Biotechnology is hard enough all on its own without investors complicating things with low-potential drugs in difficult markets. With that in mind, I don't see significant opportunity in Omeros (OMER). The company's near-term pipeline for ophthalmology and knee surgery isn't all that promising, and the early-stage pipeline of MASP-2, PDE10, PDE7, GPCR, and PPAR-gamma has far too little supporting data at this point to validate a high valuation or multiple.
OMS302 Likely To Make It, But Will It Matter?
Of all of the compounds under development at Omeros, OMS302 ('302) is both the farthest along in development and the most likely to reach the market. Unfortunately, I'm not certain there's a substantial market opportunity for it.
Only subscribers can access this article, which is part of the PRO research library covering 3,574 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: